This trial is active, not recruiting.

Conditions proteinuria, hbve-antigen
Sponsor Nanchang University
Start date January 2010
End date November 2010
Trial size 10 participants
Trial identifier NCT01152060, NCT00100504


Lamivudine treatment for HBV-DNA negative HBV-GN patients.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Eligibility Criteria

Male or female participants from 18 years up to 60 years old.

Inclusion Criteria: - Adult HBV-GN patients with biopsy-proven MN, heavy protinuria, HBsAg or HBeAg positive, HBV-DNA negative Exclusion Criteria: - Primary MN patients, HBV-DNA positive

Additional Information

Official title an Open Parallel Clinical Trial in HBV-GN Patients
Description lamivudine and predinisone treatment for HBV-DNA negative HBV-GN patients.
Trial information was received from ClinicalTrials.gov and was last updated in June 2010.
Information provided to ClinicalTrials.gov by Nanchang University.